Clinical trial
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
NCT00095030
Study timeline
Study start (unknown)2004-02-01Date precision: month
Registry last updated2010-09-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Diabetes Mellitus, Type 2unresolved
Interventions
muraglitazarDRUG
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1MiamiFlorida, United States1TorontoOntario, Canada1San AntonioTexas, United States1PittsburghPennsylvania, United States1BirminghamAlabama, United States1CincinnatiOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00095030 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.